Study | Disease, treatment | Induction treatment | Maintenance schedule | Trial design | No. of patients | Outcomes | Study arm | Control arm | P value |
---|---|---|---|---|---|---|---|---|---|
Hainsworth et al. [31] | FL/SLL | R weekly (4 times) | 4 weeks R q 6 months × 4 times | Randomized phase II | 114 | PFS (median) | 31.3 months | 7.4 months | 0.007 |
Williams et al. [30] | SLL/MZL | R weekly (4 times) | R q 3 months till PD | Phase III | 128 | TTP (median) | 4.8 years | 1.4 years | 0.012 |
Taverna et al. [37] | FL (including relapse) | R weekly (4 times) | R q 2 months for 8 month vs 5 years | Phase III | 165 | EFS | 3.4 years (8 months) | 5.3 year (5 years) | 0.14 |
Salles et al. [28] | FL | R–CVP/R–CHOP/R-FCM | R q 2 months for 2 years | Phase III | 1019 | PFS (3 years) | 74.9% | 57.6% | < 0.0001 |
Rummel et al. [35] | MZL | R–B + 2R | R q 2 months for 2 years | Randomized phase II | 104 | PFS (median) | Not reached | 92.2 months | 0.008 |
Oh (present study) | MZL | R–CVP | R q 2 months for 2 years | Phase II | 45 | PFS (3 years) | 81% | – | – |